ReviewNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2017
Renal effects of novel antiretroviral drugs.
Review in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 81 citations in OpenAlex.
- Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa.British journal of clinical pharmacology · 2024Trial
- Chronic kidney disease in patients infected with human immunodeficiency virus (HIV) in an urban cohort.PloS one · 2019Trial
- Viral suppression is associated with rising NT-proCNP levels and reduced systemic inflammation in people living with HIV.Infection · 2026Observational
- CD56bioRxiv : the preprint server for biology · 2026Article
- Biomarkers influence kidney function estimates more so than race among persons with HIV.AIDS research and therapy · 2025Article
- Transcriptional response to combination antiretroviral therapy predicts side effects and novel targets.Frontiers in pharmacology · 2025Article
- Challenges of HIV Management in an Aging Population.Current HIV/AIDS reports · 2024Review
- Management of Antiretroviral Therapy and Opportunistic Infections in People Living with HIV Undergoing Hematopoietic Stem Cell Transplant in British Columbia.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2024Article
- Pharmacokinetics of Generic Pediatric Dolutegravir Dispersible Tablet in Thai Young Children Living With HIV Weighing Below Twenty Kilograms.The Pediatric infectious disease journal · 2024Article
- Outcomes of Bariatric Surgery in People With Human Immunodeficiency Virus: A Retrospective Analysis From the ATHENA Cohort.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort.European journal of hospital pharmacy : science and practice · 2023Observational
- Recent advances in CD8Heliyon · 2023Review
- ATP/ADP biosensor organoids for drug nephrotoxicity assessment.Frontiers in cell and developmental biology · 2023Article
- How to use COVID-19 antiviral drugs in patients with chronic kidney disease.Frontiers in pharmacology · 2023Review
- Non-communicable diseases by age strata in people living with and without HIV in four African countries.Journal of the International AIDS Society · 2022Article
- Article
- Drug-Drug Interactions in People Living With HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives.Journal of clinical pharmacology · 2022Review
- Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study.International journal of environmental research and public health · 2022Article
- Drug-induced Fanconi syndrome in patients with kidney allograft transplantation.Frontiers in immunology · 2022Article
- Tenofovir alafenamide nephrotoxicity: a case report and literature review.AIDS research and therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is a critical comorbidity for patients living with HIV, with an estimated prevalence between 2.4 and 17%. Such patients are increasingly affected by diseases associated with ageing, including cardiovascular disease and CKD, and the prevalence of risk factors such as smoking and dyslipidaemia is increased in this population. Proteinuria is also now recognized as a common finding in individuals living with HIV. While combination antiretroviral (ARV) treatments reduce CKD in the HIV-infected population overall, some ARV drugs have been shown to be nephrotoxic and associated with worsening renal function. Over the last few years, several highly efficacious new ARV agents have been introduced. This brief review will look at the novel agents dolutegravir, raltegravir, elvitegravir, cobicistat, tenofovir alafenamide fumarate and atazanavir, all of which have been licensed relatively recently, and describe issues relevant to renal function, creatinine handling and potential nephrotoxicity. Given the prevalence of CKD, the wide range of possible interactions between HIV, ARV therapy, CKD and its treatments, nephrologists need to be aware of these newer agents and their possible effect on kidneys.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.